Clinical Trials

28 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

10 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT02734004 2026-01-29

MEDIOLA

BreastGastrointestinalGynecologicThoracic

264 enrolled 32 charts

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04421963 2026-01-21

ROSY-O

Phase 3 Active not recruiting

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

23 enrolled

Breast Neoplasms

NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

BreastClassical hematology

114 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

1,902 enrolled

Breast Neoplasms

NCT02484404 2025-11-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

81 enrolled

Breast Neoplasms

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

90 enrolled

Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Breast Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

54 enrolled

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

172 enrolled

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05033756 2024-05-07

COMPRENDO

11 enrolled